DHDale J. Hu

Dale J. Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dale J. Hu has a total of 164 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Research productivity and collaboration of the NIH-funded HIV vaccine trials network: A bibliometric analysis

    by Jonathan Nye, M. Patricia D'Souza, Dale Hu, Dolan Ghosh


  • Open Access

    Research productivity and collaboration of the NIH-funded HIV Vaccine Trials Network: a bibliometric analysis

    by Jonathan Nye, M.Patricia D’souza, Dale Hu, Dolan Ghosh

    Objectives To assess the scientific productivity and impact of the HIV Vaccine Trials Network (HVTN) over the last two decades and to examine how research collaboration has evolved over this time in the HIV vaccine field. Design This section does not apply since this is a bibliometric study. Methods A systematic bibliometric analysis was conducted to identify all HIV vaccine and HVTN associated publications from 1999-2019. All publications were sourced from the NLM Pubmed database and funding information was obtained from the SPIRES and iSearch databases. Both the InCites and iCite databases were utilized for impact metrics. Finally, HVTN clinical trials were obtained from clinicaltrials.gov. Multiple field normalized citation metrics, such as the relative citation ratio (RCR) and number of publications in the top 1% and 10% within their respective field, were used to gauge scientific impact of publications. Network analyses were used to examine collaboration among the most prolific researchers in the HIV vaccine research. Setting This section does not apply since this is a bibliometric study. Participants This section does not apply since this is a bibliometric study. Intervention This section does not apply since this is a bibliometric study. Results 79 clinical trials were funded by the HVTN from 1999 to 2019. These were carried out via a network of trial sites in 23 countries and 94 cities around the world. In total, 465 publications (89.5% original research articles, 7.3% reviews, and 3.2% other) acknowledged funding from the HVTN. Impact analyses using multiple field normalized metrics revealed that HVTN publications are highly cited with a mean RCR of 1.8. 10,481 HIV vaccine related publications were used to analyze collaboration in this field. Compared to the field as a whole, publications attributed to the HVTN had significantly more authors per publication (p-value < 0.001) and our network analysis found that HVTN-associated authors also had a higher degree (p-value < 0.01). Conclusions Bibliometric analysis of the last two decades of HIV vaccine research by the HVTN revealed that in addition to conducting a large number of clinical trials worldwide, the network produced high impact publications and was associated with increased collaboration among researchers. Strengths and limitations of this study To the best of our knowledge, this is the only study that has provided a systematic bibliometric analysis of the HVTN since its inception. Studies like this can illustrate overall outcomes of large clinical network programs. Advanced field normalized metrics were used to provide the most accurate measures of productivity, impact, and collaboration. Identification of HVTN publications using funding acknowledgements can lead to an underestimate of the number research articles since not all research articles include grant funding information. Variations in a single author’s name across publications can make name disambiguation difficult when performing network analyses.

  • Innovative approaches to track lymph node germinal center responses to evaluate development of broadly neutralizing antibodies in human HIV vaccine trials

    by M. Patricia D'Souza, Mary A. Allen, Jane A.G. Baumblatt, Cesar Boggiano, Shane Crotty, Christine Grady, Colin Havenar-Daughton, Antje Heit, Dale J. Hu, Nina Kunwar, et al.


  • Open Access

    Invasive Streptococcus pneumoniae infection among hospitalized patients in Jingzhou city, China, 2010-2012

    by Hui Jiang, Yang Huai, Hui Chen, Timothy M Uyeki, Maoyi Chen, Xuhua Guan, Shali Liu, Youxing Peng, Hui Yang, Jun Luo, et al.

    Streptococcus pneumoniae (Sp) is a leading cause of bacterial pneumonia, meningitis, and sepsis and a major source of morbidity and mortality worldwide. Invasive pneumococcal disease (IPD) is defined as isolation of Sp from a normally sterile site, including blood or cerebrospinal fluid. The aim of this study is to describe outcomes as well as clinical and epidemiological characteristics of hospitalized IPD case patients in central China. We conducted surveillance for IPD among children and adults from April 5, 2010 to September 30, 2012, in four major hospitals in Jingzhou City, Hubei Province. We collected demographic, clinical, and outcome data for all enrolled hospitalized patients with severe acute respiratory infection (SARI) or meningitis, and collected blood, urine, and cerebrospinal fluid (CSF) for laboratory testing for Sp infections. Collected data were entered into Epidata software and imported into SPSS for analysis. We enrolled 22,375 patients, including 22,202 (99%) with SARI and 173 (1%) with meningitis. One hundred and eighteen (118, 3%) with either SARI or meningitis were Sp positive, 32 (0.8%) from blood/CSF culture, and 87 (5%) from urine antigen testing. Of those 118 patients, 57% were aged ≥65 years and nearly 100% received antibiotics during hospitalization. None were previously vaccinated with 7-valent pneumococcal conjugate vaccine (PCV 7), 23-valent pneumococcal polysaccharide vaccine, or seasonal influenza vaccine. The main serotypes identified were 14, 12, 3, 1, 19F, 4, 5, 9V, 15 and 18C, corresponding to serotype coverage rates of 42%, 63%, and 77% for PCV7, PCV10, and PCV13, respectively. Further work is needed to expand access to pneumococcal vaccination in China, both among children and potentially among the elderly, and inappropriate use of antibiotics is a widespread and serious problem in China.


  • Open Access

    Clinical characteristics and factors associated with severe acute respiratory infection and influenza among children in Jingzhou, China

    by Yang Huai, Xuhua Guan, Shali Liu, Timothy M. Uyeki, Hui Jiang, John Klena, Jigui Huang, Maoyi Chen, Youxing Peng, Hui Yang, et al.

    Background: Influenza is an important cause of respiratory illness in children, but data are limited on hospitalized children with laboratory‐confirmed influenza in China.Methods: We conducted active surveillance for severe acute respiratory infection (SARI; fever and at least one sign or symptom of acute respiratory illness) among hospitalized pediatric patients in Jingzhou, Hubei Province, from April 2010 to April 2012. Data were collected from enrolled SARI patients on demographics, underlying health conditions, clinical course of illness, and outcomes. Nasal swabs were collected and tested for influenza viruses by reverse transcription polymerase chain reaction. We described the clinical and epidemiological characteristics of children with influenza and analyzed the association between potential risk factors and SARI patients with influenza.Results: During the study period, 15 354 children aged P<.05). Only 16% (1116/7145) of enrolled patients had received seasonal trivalent influenza vaccination within 12 months of hospital admission. Non‐vaccinated influenza cases were more likely than vaccinated influenza cases to have pneumonia (31/133, 23% vs 37/256, 15%, P<.05). severe acute respiratory infection cases aged 5–15 years diagnosed with influenza were also more likely to have a household member who smoked cigarettes compared with SARI cases without a smoking household member (54/208, 26% vs 158/960, 16%, P<.05).Conclusions: Influenza A (H3N2) virus infection was an important contributor to pneumonia requiring hospitalization. Our results highlight the importance of surveillance in identifying factors for influenza hospitalization, monitoring adherence to influenza prevention and treatment strategies, and evaluating the disease burden among hospitalized pediatric SARI patients. Influenza vaccination promotion should target children.


  • Response to Challenge Dose Among Young Adults Vaccinated for Hepatitis B as Infants: Importance of Detectable Residual Antibody to Hepatitis B Surface Antigen

    by Philip R. Spradling, Saleem Kamili, Jian Xing, Jan Drobeniuc, Dale J. Hu, Amy B. Middleman

    OBJECTIVE: To determine whether a difference in antibody to hepatitis B surface antigen (anti-HBs) response to a hepatitis B vaccine challenge dose existed among persons with a baseline anti-HBs level of 0 mIU/mL (group 1) and those with “non-zero” levels of 0.1–4.9 (group 2) and 5.0–9.9 (group 3) mIU/mL, according to the VITROS ECi anti-HBs assay.DESIGN: Subanalysis of randomized clinical trial. Response was defined as a postchallenge anti-HBs level of at least 10 mIU/mL and 4-fold rise in anti-HBs level 2 weeks after a single challenge dose of 10 vs 20 µg Engerix-B. Baseline was defined as the anti-HBs level immediately before administration of the challenge dose.SETTING: Pediatric integrated healthcare system near Houston, Texas.PARTICIPANTS: Three hundred nineteen US-born 16–19-year-olds who completed the hepatitis B vaccine series during the first year of life.RESULTS: One hundred seventy-eight persons had zero (group 1) and 141 (114 group 2 and 27 group 3) had non-zero anti-HBs levels at baseline. Response to the challenge dose was significantly higher among those with non-zero vs zero anti-HBs levels, irrespective of challenge dosage; only 1 person with a non-zero anti-HBs level failed to respond to the challenge dose (group 3, 27/27 [100%] vs group 2, 113/114 [99%] vs group 1, 145/178 [82%]; P<.0001).CONCLUSIONS: Among participants with residual anti-HBs levels less than 10 mIU/mL 16–19 years after primary hepatitis B vaccination during infancy, non-zero anti-HBs levels, with rare exception, indicated persistence of immune memory to HBsAg.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01341275Infect Control Hosp Epidemiol 2015;00(0):1–5


  • Duration of Protection After Infant Hepatitis B Vaccination Series

    by Amy B. Middleman, Carol J. Baker, Claudia A. Kozinetz, Saleem Kamili, Chi Nguyen, Dale J. Hu, Philip R. Spradling

    BACKGROUND: Little is known about duration of protection after the infant primary series of hepatitis B (HB) vaccine in settings of low HB endemicity. This study sought to determine the proportion of adolescents immunized as infants who had protective titers of antibody to hepatitis B surface antigen (anti-HBs) before and after a challenge dose of vaccine. METHODS: US-born 16- through 19-year-olds who received a recombinant HB vaccine 3-dose series initiated within 7 days of birth (group 1) or at ≥4 weeks of age (group 2) and completed by 12 months of age were enrolled. Participants had serologic testing before and 2 weeks after randomization to receive a challenge dose of 10 µg or 20 µg of Engerix-B. Baseline and postchallenge levels of anti-HBs were compared by group, challenge dosage, and demographic and behavioral characteristics. RESULTS: At baseline, 24% had protective anti-HBs levels of ≥10 IU/mL; 92% achieved protective levels after challenge dose. Although group 1 had a lower proportion of seroprotection at baseline, group and challenge dosage were not associated with postchallenge proportion of seroprotection. Being in group 2, higher test dosage, higher baseline geometric mean titer, and nonwhite race were associated with significantly higher geometric mean titer after challenge dose. CONCLUSIONS: More than 90% of study participants immunized against HB as infants exhibited a seroprotective response to a challenge dose of vaccine. Duration of protection from the primary infant HB vaccine series extended through the adolescent years in the setting of low HB endemicity.


  • Hepatitis B Testing And Access To Care Among Racial And Ethnic Minorities in Selected Communities Across the United States, 2009-2010

    by Dale J. Hu, Jian Xing, Rania A. Tohme, Youlian Liao, Henry Pollack, John W. Ward, Scott D. Holmberg

    Hepatitis B virus (HBV) infection is widely prevalent among racial and ethnic minorities in the United States; however, few data have been available regarding HBV testing and referral to care for these populations. Using survey data collected in 2009-2010 from the Racial and Ethnic Approaches to Community Health (REACH) across the U.S., we assessed rates and determinants of hepatitis B testing and access to care in 28 minority communities in the U.S. Of 53,896 respondents, 21,129 (39.2%) reported having been tested for hepatitis B. Of the 1,235 who reported testing positive, 411 (33.3%) reported currently receiving specialty care. After controlling for demographic and socioeconomic characteristics, the likelihood of having been tested for hepatitis B and receiving care if infected was higher among males, non-English speaking persons, and those having health insurance compared to their counterparts. Compared to college graduates, respondents without a college education were less likely to get tested for hepatitis B. Conclusion: These data indicate that more than half of racial/ethnic minority persons in these communities had not been tested for hepatitis B, and only about one-half of those who tested positive had ever received treatment. More state and federal efforts are needed to screen racial/ethnic minorities, especially foreign-born persons, for HBV and link those with infection to care. (Hepatology 2013;53:856–862)